Home  |  Company Overview  |  In The News  |  Our Team  |  Careers  |  Contact Us

Investment Process  |  Private Equity Funds  |  Our Funds' Investments

In The News
Intrexon Corporation Secures $25 Million Series C-2 Investment (May 7, 2008) Third Security Managing Director and CEO Randal J. Kirk Named “Outstanding Industrialist of 2008” (February 1, 2008) Clinical Data, Inc. Strengthens PGxHealth™ Leadership with Key Industry Hires (January 22, 2008) Synchrony, Inc. Secures $10 Million Series B Investment (November 29, 2007) Clinical Data Reports Strong Performance During Fiscal Second Quarter (November 14, 2007) Clinical Data To Sell Vital Scientific For $15M (October 27, 2007) Clinical Data Announces 3-For-2 Stock Split (September 12, 2007) Clinical Data Announces Positive Results from Phase III Pivotal Trial of Vilazodone for Depression (September 4, 2007 ) Third Security, LLC Hires Two New Managing Directors (August 20, 2007) Third Security, LLC Closes $250 Million Private Equity Fund (August 1, 2007) Cyntellect Completes $15.1 Million Series D Private Financing (July 25, 2007) Clinical Data Announces Exercise of Underwriters' Over-Allotment Option (July 24, 2007) Clinical Data Prices 3,000,000 Share Common Stock Offering (July 18, 2007) Clinical Data Announces Public Offering of Common Stock (July 10, 2007) Halozyme Therapeutics Names Randal J. Kirk And Kathryn E. Falberg to Board of Directors (May 16, 2007) Costas Loullis Named Vice President of R&D For Intrexon Corporation (May 15, 2007) Intrexon Corporation Closes $25 Million Series C Financing (May 11, 2007) IntelliMat(R) Becomes LevelVision(TM) And Announces Two New Digital Media Solutions (Apr. 24, 2007) Halozyme Therapeutics Announces $32.1 Million Private Financing (Apr. 24, 2007) Shire Completes Acquisition of New River (Apr. 20, 2007) Clinical Data's Vital Scientific N.V. Appoints Herman Buis as International Sales Manager (Apr. 19, 2007) Shire Successfully Completes Tender Offer for New River Shares (Apr. 18, 2007) Agilent Technologies Announces Clinical Data's Cogenics Division as its First Certified Service Provider for miRNA Microarrays (Apr. 17, 2007) Results of Extraordinary General Meeting held on 16 April 2007 (Apr. 16, 2007) Clinical Data's Cogenics Division Enters Into Alliance with Epigenomics for DNA Methylation Services (Apr. 12, 2007) Clinical Data's Vital Scientific N.V. Executes OEM Agreement with Sclavo Diagnostics INternational S.r.l. to Sell Clinical Chemistry Instrumentation in Europe, the Middle East and Africa (Apr. 11, 2007) Clinical Data adds James P Shaffer, Experienced Sales and Marketing Executive, to Lead Sales and Marketing Team for PGxHealth Division (Apr. 10, 2007) Clinical Data and Roche Sign Co-Marketing Agreement Relating to Cogenics Division Acquisition of 454 GS FLX Sequencing System (Mar. 29, 2007) PGxHealth to Present Data on Replication of Genetic Associations with Clozapine-Induced Agranulocytosis at the International Congress on Schizophrenia Research (Mar. 28, 2007) Clinical Data and Spacelabs Healthcare Enter Partnership to Promote Clinical Data's Drug-Induced Long QT Pharmacogenomics Services (Mar. 27, 2007) Clinical Data Completes Phase III Enrollment of Vilazodone for Depression (Mar. 26, 2007) Clinical Data Announces Discovery of Novel Genetic Link to Development of Schizophrenia (Mar. 20, 2007) Clinical Data Announces Purchase of Protodyne Corporation's Radius Automation System to Increase Sequencing Throughput, Lab Efficiencies, and Cost Reductions (Mar. 12, 2007) Clinical Data Announces Exercise of Warrants (Feb. 28, 2007 ) Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSETM (lisdexamfetamine dimesylate) as a Novel Treatment for ADHD (Feb 23, 2007) Clinical Data CEO Drew Fromkin Discusses Clinical Data, Inc., and its Recent Advances in Personalized Medicine (Feb. 20, 2007) New River Pharmaceuticals to be Acquired by Shire plc for $64 per Share (Feb 20, 2007) Clinical Data Announces Results for Fiscal Third Quarter 2007 Led by Revenue Growth and Continued Cash Management (Feb. 14, 2007) Clinical Data Webcast from 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Conference (Feb. 7, 2007) Clinical Data to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Conference (Feb. 6, 2007) New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Conference (Feb 5, 2007) Clinical Data Launches PGxPredict": RITUXIMAB on Schedule (Jan. 30, 2007) James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing (Jan. 25, 2007) Clinical Data Launches Pharmacogenetic Test for Clozapine-Induced Agranulocytosis on Schedule (Jan. 23, 2007) New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE™ (lisdexamfetamine dimesylate) for the Treatment of ADHD (Dec. 21, 2006) Drew Fromkin Featured in BusinessWeek CEO's 40 and Under (Dec. 21, 2006) Rheogene, Inc. Merger with Intrexon Corporation Creates Biotech Firm Targeting Gene-based Therapies (Dec. 19, 2006) Third Security Opens New Office in San Francisco (Dec. 18, 2006) Clinical Data and Lab21 Launch Cardiac Channelopathy Genetic Test in United Kingdom & Ireland (December 11, 2006) PGxHealth to Present New Data on Genetic Markers for Clozapine-Induced Agranulocytosis (CIA) at ASH (Dec. 7, 2006) Third Security Hires Ankit Desai as Managing Director (Dec. 1, 2006) Clinical Data to Present at Lazard Life Sciences Conference (Nov. 27, 2006) Clinical Data and Medicus Middleware Announce Availability of Chameleon Middleware System for Medical Labs in U.S. (Nov. 20, 2006) Clinical Data Announces Results for Fiscal 2007 Second Quarter Ended September 30, 2006 (Nov. 14, 2006) Clinical Data and Diagene in Cardiac Channelopathy Test Distribution Agreement for Germany, Switzerland and Austria (Nov. 13, 2006) Clinical Data's Vital Diagnostics Division to Exhibit at MEDICA 2006 (Nov. 10, 2006) Innnate Pharma Announces Worldwide Exclusive License with Clinical Data, Inc. for the Development of a Predictive Test for Response to Monoclonal Antibody Treatment (Nov. 9, 2006) New River Pharmaceuticals Announces Third Quarter 2006 Results (Nov. 7, 2006) Clinical Data and Quintiles Enter Strategic Alliance to Promote and Expand Clinical Data's Drug-Induced Long QT Pharmacogenomics Services (Nov. 6, 2006) Clinical Data's Total Lab Care Group in Service Agreement with Greater Cincinnati Associated Physicians, Inc. (Nov. 3, 2006) C.E. Unterberg, Towbin Life Sciences Conference Webcast (Oct. 31, 2006) Clinical Data Announces License Agreements (Oct. 31, 2006) Clinical Data's Cogenics and VWR International Announce Strategic Alliance (Oct. 30, 2006) IntelliMat, Inc. Closes $5 Million Series A Investment (Oct. 30, 2006) Clinical Data to Present at C.E. Unterberg, Towbin Conference (Oct. 26, 2006) Clinical Data Inc. Signs Exclusive License for Monoclonal Antibody Pharmacogenetic Patent Portfolio (Oct. 19, 2006) New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290 (Oct. 13, 2006) Clinical Data's Vital Diagnostics Division Executes Distribution Agreement with Canada's Inter Medico to Sell Excyte Line of ESR Analyzers (Oct. 09, 2006) New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104 (Oct. 6, 2006) Clinical Data Launches Pharmacogenetic Warfarin Response Test on Schedule (Oct. 06, 2006) Clinical Data and Algynomics to Commercialize Proprietary Genetic Pain Panel (Oct. 04, 2006) Dr. Garen Manvelian Joins New River Pharmaceuticals as Chief Medical Officer (Oct 03, 2006) Clinical Data to Discuss MicroArray Quality Control (MAQC) Project Results at Discovery 2 Diagnostics Conference (Sep. 20, 2006) Clinical Data Named for Second Year in Row as One of New England's Fastest Growing Life Sciences Companies in Deloitte's Technology Fast 50 Program (September 18) Clinical Data and PharmaCare Sign Landmark Pharmacogenomics Testing Agreement (September 15) New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III Study (September 12, 2006) New River Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare Conference (September 8, 2006) Clinical Data, Inc. Plays Integral Role in MicroArray Quality Control (MAQC) Consortium Project (September 08) Clinical Data CEO Outlines Strategy (August 18, 2006) New River Pharmaceuticals Names Dr. Samir Roy Vice President, Formulation and Manufacturing (August 17, 2006) Clinical Data's Vilazodone Patient Enrollment Over One Third Complete (August 17, 2006) Clinical Data Announces Results for Fiscal 2007 First Quarter Ended June 30, 2006 (August 15, 2006) New River Pharmaceuticals Announces Second Quarter 2006 Results (August 8, 2006) Clinical Data to Present at Drug Discovery Technology (August 8, 2006) Clinical Data Appoints New CFO ( August 7, 2006) Clinical Data to Meet with FDA Pursuant to Invitation (August 4, 2006) New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. for NRP104 (July 25, 2006) New River Pharmaceuticals Closes Sale of $135,000,000 Convertible Subordinated Notes (July 25, 2006) Vital Diagnostics Division of Clinical Data Announces Launch of Lumy Microplate Luminometer and Turbi-Quick POC Immunoanalyzer to International Market (July 25, 2006) Clinical Data Launches Excyte 20 Automated ESR Analyzer at AACC 2006 Annual Meeting and Clinical Lab Exposition (July 20, 2006) New River Pharmaceuticals Prices $125 Million Convertible Subordinated Notes; Company to Repurchase Up to $51 million in Common Stock (July 19, 2006) Clinical Data Announces FAMILION Cardiac Channelopathy Test Milestone (July 19, 2006) New River Pharmaceuticals Announces Proposal to Offer $125 Million Convertible Subordinated Notes; Company to Repurchase up to $50 million in Common Stock (July 18, 2006) Clinical Data Strengthens Cogenics Management Team with Strategic Appointments (July 10, 2006) Clinical Data Reports 2006 Year-End Results (July 5, 2006) Cogenics Collaborates with USDA Scientists to Develop DNA Markers for DNA Finger Printing and Parentage Testing of all U.S. Beef and Dairy Populations (July 2, 2006) New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409 (June 30, 2006) TRADE NEWS: Agilent Technologies Renews Cogenics as Certified Microarray Service Provider, Adds aCGH to Certification (June 28, 2006) New River Pharmaceuticals to Host Conference Call on A01, A02 and A03 Clinical Abuse Liability Studies of NRP104 (June 23, 2006) New River Pharmaceuticals Provides Detail on A02 Clinical Abuse Liability Study of NRP104 (June 20, 2006) New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 Study (June 18, 2006) Clinical Data Announces $17 Million Private Placement (June 14, 2006) New River Pharmaceuticals to Present Results from NRP104 Abuse Liability Studies (June 14, 2006) Clinical Data to Present at Fifth Annual Needham & Company Biotechnology and Medical Technology Conference (June 12, 2006) Clinical Data Announces 2006 Launch of Genetic Test for Warfarin Response (June 6, 2006) Clinical Data's Cogenics Division Announces Renewed DNA Sequencing Contract with Medical Research Council (June 6, 2006) New River Pharmaceuticals to Present at the Friedman Billings Ramsey 2006 Growth Investor Conference (May 30, 2006) Positive NRP104 Study Results Presented at American Psychiatric Association Meeting (May 24, 2006) New River Pharmaceuticals Initiates Pivotal Phase III Trial of NRP104 for Adult ADHD (May 23, 2006) Clinical Data Announces Private Purchase of Shares (May 19, 2006) New River Pharmaceuticals Added to NASDAQ Biotech Index (May 17, 2006) Clinical Data Announces Management Reorganization and Plan to Spin Off Vilazodone Business (May 15, 2006) Clinical Data and Duke University in Pharmacogenomics Research and Commercialization Collaboration (May 11, 2006) New River Pharmaceuticals Announces First Quarter 2006 Results (May 11, 2006) Clinical Data Launches New Integrated Website (May 10, 2006) Clinical Data and Maple Leaf Foods in Agreement to Develop Enhanced Pork Traceability System (May 8, 2006) New River Pharmaceuticals to Present at the Baird 2006 Growth Stock Conference (May 8, 2006) Third Security Hires William K. Hsu as Managing Director (May 1, 2006) Clinical Data Announces Termination of Rule 10b5-1 Pre-Arranged Stock Sales Plan (April 24, 2006) Clinical Data Achieves Validation of Genetic Biomarker for Determining Risk of Clozapine Induced Agranulocytosis (April 19, 2006) New River Pharmaceuticals to Present at the UBS Global Specialty Pharmaceuticals Conference (April 19, 2006) New River Pharmaceuticals Names John Thottathil Chief Scientific Officer (April 11, 2006) Clinical Data to Participate at BIO 2006 Convention (April 7, 2006) Clinical Data Initiates Patient Enrollment for Vilazodone Phase 3 Clinical Trial (March 30, 2006) Barbara Greising Joins Clinical Data's PGxHealth as Division Vice President (March 28, 2006) New River Pharmaceuticals Announces Year-End Results (March 10, 2006) Clinical Data Acquires GENOME Express to Enhance European Expansion (March 7, 2006) Clinical Data Launches PGxHEALTH™ and COGENICS™ (March 1, 2006) Intrexon Corporation raises $1 million for advancing its subcellular tools (March 1, 2006) Clinical Data Receives FDA 510(k) Clearance for Nanopia Wide Range CRP Assay (February 22, 2006) Clinical Data Summarizes Progress and Achievements and Updates Strategy and Milestones (February 21, 2006) Synchrony, Inc. Closes $5 Million Series A Investment (February 21, 2006) Third Security Promotes Tad Fisher to Managing Director (Feb. 15, 2006) Clinical Data Announces Results for Fiscal Third Quarter Ended December 31, 2005 (February 14, 2006) New River Provides Clinical Test Results on NRP290 and Receives $50 Million Payment from Shire (February 7, 2006) New River Pharmaceuticals Announces NRP104 NDA Accepted for Review (January 27, 2006) Clinical Data Valazadone Biomarkers Research Profiled in BioWorld (January 27, 2006) Clinical Data Initiates Pivotal Phase III Trial for Novel Antidepressant (January 26, 2006) Clinical Data Announces Reorganization to Emphasize Core Pharmacogenomics Business (January 20, 2006) Clinical Data Announces Presentation at Diagnostics Asia 2006 (January 17, 2006) Clinical Data Repurchases Xmark Fund Warrants and Retires Related Debt (January 17, 2006) New River Pharmaceuticals to Present Clinical Data on NRP290 at Merrill Lynch Global Pharmaceutical Conference (January 17, 2006) Clinical Data, Inc. Announces Collaborative Research Agreement with University of Pittsburgh Cancer Institute for Metabolomics Analysis of Lung Cancer Samples (January 12, 2006) Clinical Data Acquires Electra Lab (December 28, 2005) New River Announces 2-for-1 Stock Split (December 20, 2005) Clinical Data Completes Acquisition of Icoria, Inc. (December 20, 2005) Clinical Data Announces Approval to List its Securities on the NASDAQ National Market (December 19, 2005) New River Pharmaceuticals Names Robert Colucci Vice President, Clinical Development (December 13, 2005) New River Pharmaceuticals Files New Drug Application on NRP104 for Treatment of Pediatric ADHD (December 7, 2005) New River Pharmaceuticals to Present at First Albany Capital Annual Growth Conference (November 23, 2005) Clinical Data Announces $12 Million Private Placement (November 18, 2005) Clinical Data Reports Profitable Second Quarter and Six-Month Results (November 14, 2005) New River Pharmaceuticals Announces Third Quarter 2005 Results (November 14, 2005) Clinical Data Appoints Carol Reed Chief Medical Officer and John Schultz Senior Vice President, Business Development (October 31, 2005) Clinical Data Appoints Drew Fromkin, Former Merck-Meco Executive, As Chief Marketing Officer (October 21, 2005) Clinical Data Completes Acquisition of Genaissance Pharmaceuticals (October 7, 2005) New River Pharmaceuticals to Present at UBS Global Life Sciences Conference (September 22, 2005) Clinical Data, Inc. to Acquire Icoria, Inc. (September 20, 2005) New River Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference (September 13, 2005) New River Provides First Clinical Test Results on NRP290 (September 12, 2005) New River Pharmaceuticals to Present at Bear Stearns 18th Annual Healthcare Conference (September 7, 2005) New River Pharmaceuticals Announces Second Quarter 2005 Results (August 12, 2005) New River Updates Preclinical Pipeline (August 9, 2005) Clinical Data Receives FDA 510K Clearance For The New EXCYTE™ Hematology Analyzer (August 8, 2005) Third Security Sells Investment Advisor Cook Mayor Taylor To Management-Led Group (August 1, 2005) Clinical Data Sues Carolina Liquid Chemistries For Misappropriation Of Trade Secrets And Other Related Claims (July 26, 2005) New River Pharmaceuticals' CEO and CFO Each Adopt Rule 10b5-1 Trading Plans (July 15, 2005) New River Enters into a Licensing Agreement with the University of California and Gallo Center to Investigate a Technology to Reduce Opioid Tolerance (July 8, 2005) New River Files Investigational New Drug Application for NRP290 to Treat Acute Pain (June 28, 2005) New River Pharmaceuticals Inc. Added to Russell 3000(R) Index (June 27, 2005) Clinical Data to Reports Record Fiscal Year 2005 Results (June 24, 2005) Clinical Data to Acquire Genaissance Pharmaceuticals (June 21, 2005) Depomed and New River Enter Into Development and License Agreement (June 6, 2005) New River Provides Preclinical Test Results on NRP290 (June 1, 2005) New River to Present at FBR 9th Annual Growth Investor Conference (May 26, 2005) NRP104 Meets Primary and Secondary Endpoints in Phase 3 Study (May 23, 2005) Genomatix Announces $500,000 Investment (May 16, 2005) New River Pharmaceuticals Announces First Quarter 2005 Results (May 9, 2005) New River Pharmaceuticals to Present Phase 3 Data at UBS Global Pharmaceuticals Conference (May 6, 2005) James Mulry Appointed Director of Marketing, Hematology (April 15, 2005) Clinical Data to Distribute Daiichi Pure Chemicals' hsCRP Assay (April 11, 2005) New River Pharmaceuticals Announces Year-end Results (April 1, 2005) Clinical Data Signs Master Distribution Agreement For New PSA Assay With Daiichi Pure Chemicals (February 14, 2005) Clinical Data Reports Record Profits (February 11, 2005) Clinical Data Obtains Exclusive Distribution Rights for Melet Schloesing Laboratories' Line of Hematology Analyzers and Reagents (February 1, 2005) Clinical Data Declares Seventeenth Consecutive Quartery Cash Dividend (January 13, 2005) Clinical Data Names Randal J. Kirk New Chairman (December 22, 2004) Clinical Data Reports Second Quarter and Record Six-Month Results (November 12, 2004) Clinical Data Triples Quarterly Cash Dividend To $0.03 Per Share Sixteenth Consecutive Quarterly Dividend (September 21, 2004) New River Pharmaceuticals Inc. Files 10-Q for the Second Quarter (September 17, 2004) Joseph Vacante Appointed Vice President of Sales For North America (September 10, 2004) New River Pharmaceuticals to Present at the 17th Annual Bear Stearns Healthcare Conference (Sep 1, 2004) New River Pharmaceuticals' NRP104 Receives FDA Fast Track Designation for Treatment of Cocaine Dependence (Aug 31, 2004) Clinical Data Reports Record First Quarter Revenue And Operating Profit (August 12, 2004) New River Pharmaceuticals Announces Initial Public Offering (Aug 5, 2004) New River Pharmaceuticals Announces Proposed Auction-Based Initial Public Offering (Jul 19, 2004) Clinical Data Declares Fifteenth Consecutive Quarterly Cash Dividend (July 2, 2004) Clinical Data Reports Record Fourth Quarter And Fiscal Year 2004 Results (June 25, 2004) Clinical Data Declares Fourteenth Consecutive Quarterly Cash Dividend (April 19, 2004) Clinical Data Will Not Enhance Offer For Moore Medical (March 3, 2004) Clinical Data Increases Offer By $2 Per Share In Cash (February 26, 2004) Clinical Data Offers To Merge With Moore Medical Corp. (February 24, 2004) Roanoke-New River Valley Investment Fund (Feb 19, 2004) Clinical Data Reports Profitable Third Quarter (February 17, 2004) Clinical Data Declares Thirteenth Consecutive Quarterly Cash Dividend (January 16, 2004) Clinical Data S-3 of Common Stock Declared Effective by SEC (January 13, 2004) Clinical Data Names Garth “Gus” Gardner as Chief Operating Officer (January 5, 2004) Clinical Data Files Form S-3 Shelf Registration for 2,672,500 Shares of Common Stock (December 18, 2003) Fund Tries to Take Root Amid Storm (Nov 03, 2003) Clinical Data Declares Twelfth Consecutive Quarterly Cash Dividend (October 7, 2003) Novitron International Changes Name to Clinical Data (Oct 03, 2003) Novitron International Reports First Quarter Results Revenues Increased 216% (Aug 14, 2003) Novitron International Names Senior Management (Jun 10, 2003) Novitron International Inc Files (8-K) Disclosing Changes in Control of Registrant, Acquisition or Disposition of Assets and Financial Statements & Exhibits (May 12, 2003) Cook Mayer and Taylor, a growing small and mid-cap Investment Management Firm, joins Third Security's Asset Management Group (Jan 24, 2003) Novitron International to Acquire Assets of Elan Diagnostics (Dec 9, 2002) Novitron International to Acquire Group Practice Services (Nov 15, 2002) Novitron International, Inc. has signed an agreement and plan of merger with Landmark Scientific, Inc (Aug 21, 2002) DJ SciClone Pharma/Hldr Vote -2: Kirk Holds 6% Stake (May 17, 2002) Scios Announces R.J. Kirk Resigns From Board of Directors ( May 15, 2002) Making it Happen - R.J. Kirk (Feb 3, 2002) Third Security, Laidlaw Global agree to new deal (Dec 28,2001) Laidlaw Global Corp. Signs Funding Agreement (Dec 4, 2001) Radford Donor Gives Based on the Person; Kirk Donated $175,000 to Mark Earley (June 16, 2001) Scios and R. J. Kirk Agree to End Proxy Contest; Parties Focused On Building Stockholder Value (Jan 31, 2000) Largest Stockholder Blasts Scios Board's Enrichment Schemes (Jan 13, 2000) Scios Shareholder Withdraws Proposal to Sell Scios In Favor of Kirk, Proxy Solicitation to Replace Board (Dec 16, 1999) Radford Alum Sets Up Funds for Chinese Curriculum (May 03, 1999)
© Copyright 2008 Third Security, LLC. All rights reserved. Terms of Use